Structured Review

Millipore native ovalbumin protein ova
Native Ovalbumin Protein Ova, supplied by Millipore, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/native ovalbumin protein ova/product/Millipore
Average 86 stars, based on 1 article reviews
Price from $9.99 to $1999.99
native ovalbumin protein ova - by Bioz Stars, 2024-04
86/100 stars

Images


Structured Review

Millipore anti ovalbumin antibody anti ova
Anti Ovalbumin Antibody Anti Ova, supplied by Millipore, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti ovalbumin antibody anti ova/product/Millipore
Average 86 stars, based on 1 article reviews
Price from $9.99 to $1999.99
anti ovalbumin antibody anti ova - by Bioz Stars, 2024-04
86/100 stars

Images


Structured Review

Millipore ovalbumin ova
Ovalbumin Ova, supplied by Millipore, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ovalbumin ova/product/Millipore
Average 86 stars, based on 1 article reviews
Price from $9.99 to $1999.99
ovalbumin ova - by Bioz Stars, 2024-04
86/100 stars

Images


Structured Review

Millipore ovalbumin ova
Ovalbumin Ova, supplied by Millipore, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ovalbumin ova/product/Millipore
Average 86 stars, based on 1 article reviews
Price from $9.99 to $1999.99
ovalbumin ova - by Bioz Stars, 2024-04
86/100 stars

Images


Structured Review

Millipore ovalbumin ova
Lung ILC2s in <t>an</t> <t>ovalbumin</t> <t>(OVA)-induced</t> asthma model with intranasal rIL-3 application. (A) Experimental design for the induction of allergic asthma in wild-type (WT) mice treated with rIL-3 for the analysis of lung ILC2s. (B) Cartoon on the differentiation of different ILC2 subpopulations. (C–F) Flow cytometry analysis of ILC2 after in vitro differentiation. Flow cytometry analysis of lung ILC2s (%) (C, D) ; flow cytometry analysis of GATA3+ ST2 int . ILC2 (E, F) in the lung of WT mice with asthma and with and without additional rIL-3 treatment during sensitization or challenge phase (n = 6/7/7). (G) Cartoon on the mechanism of IL-3 involvement in ST2 shedding from ILC2. Data are presented as means ± SEMs. One-way ANOVA or Kruskal–Wallis test was used to calculate statistical significance. *p ≤ 0.05; **p ≤ 0.01.
Ovalbumin Ova, supplied by Millipore, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ovalbumin ova/product/Millipore
Average 86 stars, based on 1 article reviews
Price from $9.99 to $1999.99
ovalbumin ova - by Bioz Stars, 2024-04
86/100 stars

Images

1) Product Images from "An Immunoregulatory Role of Interleukin-3 in Allergic Asthma"

Article Title: An Immunoregulatory Role of Interleukin-3 in Allergic Asthma

Journal: Frontiers in Immunology

doi: 10.3389/fimmu.2022.821658

Lung ILC2s in an ovalbumin (OVA)-induced asthma model with intranasal rIL-3 application. (A) Experimental design for the induction of allergic asthma in wild-type (WT) mice treated with rIL-3 for the analysis of lung ILC2s. (B) Cartoon on the differentiation of different ILC2 subpopulations. (C–F) Flow cytometry analysis of ILC2 after in vitro differentiation. Flow cytometry analysis of lung ILC2s (%) (C, D) ; flow cytometry analysis of GATA3+ ST2 int . ILC2 (E, F) in the lung of WT mice with asthma and with and without additional rIL-3 treatment during sensitization or challenge phase (n = 6/7/7). (G) Cartoon on the mechanism of IL-3 involvement in ST2 shedding from ILC2. Data are presented as means ± SEMs. One-way ANOVA or Kruskal–Wallis test was used to calculate statistical significance. *p ≤ 0.05; **p ≤ 0.01.
Figure Legend Snippet: Lung ILC2s in an ovalbumin (OVA)-induced asthma model with intranasal rIL-3 application. (A) Experimental design for the induction of allergic asthma in wild-type (WT) mice treated with rIL-3 for the analysis of lung ILC2s. (B) Cartoon on the differentiation of different ILC2 subpopulations. (C–F) Flow cytometry analysis of ILC2 after in vitro differentiation. Flow cytometry analysis of lung ILC2s (%) (C, D) ; flow cytometry analysis of GATA3+ ST2 int . ILC2 (E, F) in the lung of WT mice with asthma and with and without additional rIL-3 treatment during sensitization or challenge phase (n = 6/7/7). (G) Cartoon on the mechanism of IL-3 involvement in ST2 shedding from ILC2. Data are presented as means ± SEMs. One-way ANOVA or Kruskal–Wallis test was used to calculate statistical significance. *p ≤ 0.05; **p ≤ 0.01.

Techniques Used: Flow Cytometry, In Vitro


Structured Review

Millipore surrogate antigen ovalbumin b16 ova
Blimp1 + Treg and T FR cells are accumulated in the tumor. a-b ) Blimp1-YFP reporter mice ( n = 5) were inoculated with <t>B16-OVA</t> and immunized with NP-OVA/CFA at day 0 and NP-OVA/IFA at day 7. Cells from spleens and tumors were analyzed at day 21 by flow cytometry. Blimp1 = YFP. a ) Frequencies of indicated subsets. eTreg: CD62L lo CD44 hi Treg. b ) Expression of indicated molecules in Blimp1 + Foxp3 + Treg cells. c ) Foxp3 YFP-Cre mice (n = 5) were established with B16-OVA/NP-OVA model as in a. left , expression of T FR (PD-1 + Bcl6 + Foxp3 + CD4 + CD3 + ), T FH (PD-1 + Bcl6 + Foxp3 − CD4 + CD3 + ) and GC B-cells (GL-7 + Fas + CD19 + ); right , Ratios of T FR :T FH or T FR :GC B in the spleen or tumor. Data represent one of two (a-b) or at least three (c) independent experiments. d ) Representative analysis of indicated molecules in Treg cells (CD25 + CD127 − CD4 + CD3 + ) from melanoma metastatic lung (M) or uninvolved lung tissue (Control, C) of the same patient. e ) Frequency of Treg cells and mean fluorescence intensity (MFI) of indicated molecules as presented in d. f ) T FR (PD-1 + CXCR5 + CD25 + CD127 − CD4 + CD3 + ) and CD27 + CD38 + B-cells (gated on IgD − CD19 + CD3 − ) from melanoma metastatic lung (M) or uninvolved lung tissue (C) of the same patient. g ) Frequency of each subset in f. Other melanoma metastatic tissues are included in e and g: 1, lung; 2, liver; 3, lymph node. h ) IF staining of T FR (CXCR5 + Foxp3 + CD4 + ) and T FH (CXCR5 + Foxp3 − CD4 + ) cells in two FFPE melanoma metastatic lymph node sections (160 ×). Insets with a 4-fold magnification highlight T FR (arrowheads) and T FH (*) cells. i-j ) Relative fractions, indicated by % with matched colors, of CXCR5 hi and CXCR5 lo (based on median expression value cutoff) patients within FOXP3 hi ( i ) or PRDM1 hi ( j ) group (top 33%) in primary and metastatic patients from the TCGA-SKCM dataset. ns, no significance, * P < 0.05, ** P < 0.01 and **** P < 0.0001 (a,c, unpaired two-tailed Student’s t-test; e,g, paired two-tailed Student’s t-test). Bars, mean ± SEM
Surrogate Antigen Ovalbumin B16 Ova, supplied by Millipore, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/surrogate antigen ovalbumin b16 ova/product/Millipore
Average 86 stars, based on 1 article reviews
Price from $9.99 to $1999.99
surrogate antigen ovalbumin b16 ova - by Bioz Stars, 2024-04
86/100 stars

Images

1) Product Images from "Remodeling of the tumor microenvironment via disrupting Blimp1 + effector Treg activity augments response to anti-PD-1 blockade"

Article Title: Remodeling of the tumor microenvironment via disrupting Blimp1 + effector Treg activity augments response to anti-PD-1 blockade

Journal: Molecular Cancer

doi: 10.1186/s12943-021-01450-3

Blimp1 + Treg and T FR cells are accumulated in the tumor. a-b ) Blimp1-YFP reporter mice ( n = 5) were inoculated with B16-OVA and immunized with NP-OVA/CFA at day 0 and NP-OVA/IFA at day 7. Cells from spleens and tumors were analyzed at day 21 by flow cytometry. Blimp1 = YFP. a ) Frequencies of indicated subsets. eTreg: CD62L lo CD44 hi Treg. b ) Expression of indicated molecules in Blimp1 + Foxp3 + Treg cells. c ) Foxp3 YFP-Cre mice (n = 5) were established with B16-OVA/NP-OVA model as in a. left , expression of T FR (PD-1 + Bcl6 + Foxp3 + CD4 + CD3 + ), T FH (PD-1 + Bcl6 + Foxp3 − CD4 + CD3 + ) and GC B-cells (GL-7 + Fas + CD19 + ); right , Ratios of T FR :T FH or T FR :GC B in the spleen or tumor. Data represent one of two (a-b) or at least three (c) independent experiments. d ) Representative analysis of indicated molecules in Treg cells (CD25 + CD127 − CD4 + CD3 + ) from melanoma metastatic lung (M) or uninvolved lung tissue (Control, C) of the same patient. e ) Frequency of Treg cells and mean fluorescence intensity (MFI) of indicated molecules as presented in d. f ) T FR (PD-1 + CXCR5 + CD25 + CD127 − CD4 + CD3 + ) and CD27 + CD38 + B-cells (gated on IgD − CD19 + CD3 − ) from melanoma metastatic lung (M) or uninvolved lung tissue (C) of the same patient. g ) Frequency of each subset in f. Other melanoma metastatic tissues are included in e and g: 1, lung; 2, liver; 3, lymph node. h ) IF staining of T FR (CXCR5 + Foxp3 + CD4 + ) and T FH (CXCR5 + Foxp3 − CD4 + ) cells in two FFPE melanoma metastatic lymph node sections (160 ×). Insets with a 4-fold magnification highlight T FR (arrowheads) and T FH (*) cells. i-j ) Relative fractions, indicated by % with matched colors, of CXCR5 hi and CXCR5 lo (based on median expression value cutoff) patients within FOXP3 hi ( i ) or PRDM1 hi ( j ) group (top 33%) in primary and metastatic patients from the TCGA-SKCM dataset. ns, no significance, * P < 0.05, ** P < 0.01 and **** P < 0.0001 (a,c, unpaired two-tailed Student’s t-test; e,g, paired two-tailed Student’s t-test). Bars, mean ± SEM
Figure Legend Snippet: Blimp1 + Treg and T FR cells are accumulated in the tumor. a-b ) Blimp1-YFP reporter mice ( n = 5) were inoculated with B16-OVA and immunized with NP-OVA/CFA at day 0 and NP-OVA/IFA at day 7. Cells from spleens and tumors were analyzed at day 21 by flow cytometry. Blimp1 = YFP. a ) Frequencies of indicated subsets. eTreg: CD62L lo CD44 hi Treg. b ) Expression of indicated molecules in Blimp1 + Foxp3 + Treg cells. c ) Foxp3 YFP-Cre mice (n = 5) were established with B16-OVA/NP-OVA model as in a. left , expression of T FR (PD-1 + Bcl6 + Foxp3 + CD4 + CD3 + ), T FH (PD-1 + Bcl6 + Foxp3 − CD4 + CD3 + ) and GC B-cells (GL-7 + Fas + CD19 + ); right , Ratios of T FR :T FH or T FR :GC B in the spleen or tumor. Data represent one of two (a-b) or at least three (c) independent experiments. d ) Representative analysis of indicated molecules in Treg cells (CD25 + CD127 − CD4 + CD3 + ) from melanoma metastatic lung (M) or uninvolved lung tissue (Control, C) of the same patient. e ) Frequency of Treg cells and mean fluorescence intensity (MFI) of indicated molecules as presented in d. f ) T FR (PD-1 + CXCR5 + CD25 + CD127 − CD4 + CD3 + ) and CD27 + CD38 + B-cells (gated on IgD − CD19 + CD3 − ) from melanoma metastatic lung (M) or uninvolved lung tissue (C) of the same patient. g ) Frequency of each subset in f. Other melanoma metastatic tissues are included in e and g: 1, lung; 2, liver; 3, lymph node. h ) IF staining of T FR (CXCR5 + Foxp3 + CD4 + ) and T FH (CXCR5 + Foxp3 − CD4 + ) cells in two FFPE melanoma metastatic lymph node sections (160 ×). Insets with a 4-fold magnification highlight T FR (arrowheads) and T FH (*) cells. i-j ) Relative fractions, indicated by % with matched colors, of CXCR5 hi and CXCR5 lo (based on median expression value cutoff) patients within FOXP3 hi ( i ) or PRDM1 hi ( j ) group (top 33%) in primary and metastatic patients from the TCGA-SKCM dataset. ns, no significance, * P < 0.05, ** P < 0.01 and **** P < 0.0001 (a,c, unpaired two-tailed Student’s t-test; e,g, paired two-tailed Student’s t-test). Bars, mean ± SEM

Techniques Used: Flow Cytometry, Expressing, Fluorescence, Staining, Two Tailed Test

Delayed tumor growth and enhanced anti-tumor effector responses in mice with Foxp3-specific deletion of Blimp1. Blimp1 WT ( Foxp3 YFP-Cre ), Het ( Prdm1 fl/+ Foxp3 YFP-Cre ) and KO ( Prdm1 fl/fl Foxp3 YFP-Cre ) mice were inoculated with MC38 ( n = 6 per group) ( a ), B16-F10 (WT: n = 4; KO: n = 6) ( b ) or B16-OVA at day 0 and immunized with NP-OVA at days 0, 7 (as Fig. ) (WT: n = 6; KO: n = 14) ( c ) or B16-OVA at day 0 and vaccinated with GVAX at days 1, 3 and 7 (WT: n = 4; Het: n = 4; KO: n = 6) ( d ), and tumor growth was monitored. e ) Analysis of IFNγ, TNFα and GzmB expression in TIL CD4 + Foxp3 − Teff, CD8 + T-cells and NK cells from mice as in c. f ) Analysis and quantitation of TIL CD11c + MHCII + DC (WT: n = 3; KO: n = 4). g ) Expression of MHCII and CD206 on TIL F4/80 + macrophages, and ratio of MHCII + M1:CD206 + M2 (WT: n = 3; KO: n = 4). Data represent one of two (a-b,d,f-g) or at least three (e) or are pooled from two (c) independent experiments. * P < 0.05, ** P < 0.01, *** P < 0.001 and **** P < 0.0001 (a-d, two-way ANOVA with sidak’s comparisons test (a-c) or with tukey’s test (d), black: KO compared to WT, red: Het compared to WT; f,g, unpaired two-tailed Student’s t-test). Bars, mean ± SEM
Figure Legend Snippet: Delayed tumor growth and enhanced anti-tumor effector responses in mice with Foxp3-specific deletion of Blimp1. Blimp1 WT ( Foxp3 YFP-Cre ), Het ( Prdm1 fl/+ Foxp3 YFP-Cre ) and KO ( Prdm1 fl/fl Foxp3 YFP-Cre ) mice were inoculated with MC38 ( n = 6 per group) ( a ), B16-F10 (WT: n = 4; KO: n = 6) ( b ) or B16-OVA at day 0 and immunized with NP-OVA at days 0, 7 (as Fig. ) (WT: n = 6; KO: n = 14) ( c ) or B16-OVA at day 0 and vaccinated with GVAX at days 1, 3 and 7 (WT: n = 4; Het: n = 4; KO: n = 6) ( d ), and tumor growth was monitored. e ) Analysis of IFNγ, TNFα and GzmB expression in TIL CD4 + Foxp3 − Teff, CD8 + T-cells and NK cells from mice as in c. f ) Analysis and quantitation of TIL CD11c + MHCII + DC (WT: n = 3; KO: n = 4). g ) Expression of MHCII and CD206 on TIL F4/80 + macrophages, and ratio of MHCII + M1:CD206 + M2 (WT: n = 3; KO: n = 4). Data represent one of two (a-b,d,f-g) or at least three (e) or are pooled from two (c) independent experiments. * P < 0.05, ** P < 0.01, *** P < 0.001 and **** P < 0.0001 (a-d, two-way ANOVA with sidak’s comparisons test (a-c) or with tukey’s test (d), black: KO compared to WT, red: Het compared to WT; f,g, unpaired two-tailed Student’s t-test). Bars, mean ± SEM

Techniques Used: Expressing, Quantitation Assay, Two Tailed Test

TIL Blimp1-deficient Treg cells convert into effector T-cells and display impaired suppressive function. a-c ) Analysis of TIL Treg cells ( n = 7 per group) from mice as in Fig. c. Quantitation of frequency and Foxp3 MFI of Treg cells ( a ); IFNγ, TNFα and GzmB expression in Treg cells ( b ) or frequency of TIL Treg cells expressing these molecules ( c ). d ) B16-OVA/GVAX model was established as in Fig. d. IFNγ, TNFα and GzmB expression in TIL Treg cells (n = 4 per group). e ) In vitro suppression of CTV-labelled CD8 + T-cell proliferation performed in duplicates per experimental group. Percent suppression is shown. WT: Foxp3 YFP-Cre , KO: Prdm1 fl/fl Foxp3 YFP-Cre . SP: spleen; TU: tumor. Data represent one of at least three (a-c) or two (d-e) independent experiments. * P < 0.05, ** P < 0.01, *** P < 0.001 and **** P < 0.0001 (a,c,d,e, unpaired two-tailed Student’s t-test). Bars, mean ± SEM
Figure Legend Snippet: TIL Blimp1-deficient Treg cells convert into effector T-cells and display impaired suppressive function. a-c ) Analysis of TIL Treg cells ( n = 7 per group) from mice as in Fig. c. Quantitation of frequency and Foxp3 MFI of Treg cells ( a ); IFNγ, TNFα and GzmB expression in Treg cells ( b ) or frequency of TIL Treg cells expressing these molecules ( c ). d ) B16-OVA/GVAX model was established as in Fig. d. IFNγ, TNFα and GzmB expression in TIL Treg cells (n = 4 per group). e ) In vitro suppression of CTV-labelled CD8 + T-cell proliferation performed in duplicates per experimental group. Percent suppression is shown. WT: Foxp3 YFP-Cre , KO: Prdm1 fl/fl Foxp3 YFP-Cre . SP: spleen; TU: tumor. Data represent one of at least three (a-c) or two (d-e) independent experiments. * P < 0.05, ** P < 0.01, *** P < 0.001 and **** P < 0.0001 (a,c,d,e, unpaired two-tailed Student’s t-test). Bars, mean ± SEM

Techniques Used: Quantitation Assay, Expressing, In Vitro, Two Tailed Test

Foxp3 specific deletion of Blimp1 results in increased anti-tumor humoral immunity. Analysis was performed on splenic or tumoral cells from mice bearing B16-OVA (as in Fig. c). Frequency of T FR , T FH and GC B-cells (as gated in Fig. c) in spleen ( a ) or tumor ( b ) (n = 5 per group). c ) Serum total IgG, IgE and anti-OVA IgG, IgE titers ( n = 8 per group). d ) The relationship of serum IgE titers and tumor sizes in KO mice. e ) B16-OVA/GVAX model was established as in Fig. d. Serum total IgE and anti-OVA IgE titers (WT: n = 6; KO: n = 5). The value 0 is used to indicate the undetectable anti-OVA IgE titers in c,e. f ) Representative IF staining of T (CD3), B (B220), or IgE in the tumor (100 ×). Arrowheads, T/B clusters; *, IgE. g ) Intracellular staining and quantitation of IgE in CD19 + B-cells (n = 5 per group). WT: Foxp3 YFP-Cre , KO: Prdm1 fl/fl Foxp3 YFP-Cre . h-j ) Transfer of Blimp1-deficient T FR cells induces better anti-tumor response. WT: Rosa26 ERT2-Cre ; del: Prdm1 fl/fl Rosa26 ERT2-Cre . h ) Schematic diagram of experiment. i ) Tamoxifen-induced deletion of Blimp1 in T FR cells delayed tumor growth (n = 3 per group). j ) Serum antibody titers (WT: n = 5; del: n = 6). Data represent one of at least three (a-d, f) or two (e,g,i) or are pooled from two (j) independent experiments. ns, no significance, * P < 0.05, ** P < 0.01 and *** P < 0.001 (a,b,c,e,g,j, unpaired two-tailed Student’s t-test; d, Spearman’s r ; i, two-way ANOVA with Sidak’s comparisons test). Bars, mean ± SEM
Figure Legend Snippet: Foxp3 specific deletion of Blimp1 results in increased anti-tumor humoral immunity. Analysis was performed on splenic or tumoral cells from mice bearing B16-OVA (as in Fig. c). Frequency of T FR , T FH and GC B-cells (as gated in Fig. c) in spleen ( a ) or tumor ( b ) (n = 5 per group). c ) Serum total IgG, IgE and anti-OVA IgG, IgE titers ( n = 8 per group). d ) The relationship of serum IgE titers and tumor sizes in KO mice. e ) B16-OVA/GVAX model was established as in Fig. d. Serum total IgE and anti-OVA IgE titers (WT: n = 6; KO: n = 5). The value 0 is used to indicate the undetectable anti-OVA IgE titers in c,e. f ) Representative IF staining of T (CD3), B (B220), or IgE in the tumor (100 ×). Arrowheads, T/B clusters; *, IgE. g ) Intracellular staining and quantitation of IgE in CD19 + B-cells (n = 5 per group). WT: Foxp3 YFP-Cre , KO: Prdm1 fl/fl Foxp3 YFP-Cre . h-j ) Transfer of Blimp1-deficient T FR cells induces better anti-tumor response. WT: Rosa26 ERT2-Cre ; del: Prdm1 fl/fl Rosa26 ERT2-Cre . h ) Schematic diagram of experiment. i ) Tamoxifen-induced deletion of Blimp1 in T FR cells delayed tumor growth (n = 3 per group). j ) Serum antibody titers (WT: n = 5; del: n = 6). Data represent one of at least three (a-d, f) or two (e,g,i) or are pooled from two (j) independent experiments. ns, no significance, * P < 0.05, ** P < 0.01 and *** P < 0.001 (a,b,c,e,g,j, unpaired two-tailed Student’s t-test; d, Spearman’s r ; i, two-way ANOVA with Sidak’s comparisons test). Bars, mean ± SEM

Techniques Used: Staining, Quantitation Assay, Two Tailed Test

Sera from Prdm1 fl/fl Foxp3 YFP-Cre tumor-bearing mice increase the anti-tumor activity of macrophages. a-b ) B16-OVA model was established as in Fig. c. IF staining of IgE and CD68 in the tumor and quantitation of IgE + CD68 + and IgE + CD68 − cells ( a ); or IF staining of FcεR1α and CD68 in the tumor ( b ). Each dot represents the counted numbers within a field of view (160 ×). WT: n = 15 views from 6 mice; KO: n = 14 views from 6 mice. c-d ) BMDMs were co-cultured with CTV-labelled B16-OVA cells treated with or without a same volume of sera (2.5 μl, 1.25% of the total culture) collected from WT or Prdm1 fl/fl Foxp3 YFP - Cre (KO) tumor-bearing mice for 2 h ( c ) or overnight ( d ) in quadruplicates. In a group, sera were pre-treated with anti-IgE (α-IgE). c ) BMDMs with phagocytosed B16-OVA cells were indicated as CTV + F4/80 + cells ( upper left , representative F4/80 + plot; lower left , representative histogram of CTV expression gated on F4/80 + cells; right , quantitation). d ) Percent tumor killing is shown after quantifying dead tumor cells (CTV + cells positive for viability-dye). Tumor cells alone treated with sera were included as controls. Triangles, tumor cells and BMDMs with no sera added. ns, no significance, * P < 0.05, ** P < 0.01, *** P < 0.001 and **** P < 0.0001 (a,c,d, unpaired two-tailed Student’s t-test). Bars, mean ± SEM. e ) The correlation of CD86 and FCER1A expression in top 25% CD68 hi SKCM patients from the TCGA dataset ( n = 110) was analyzed by Pearson correlation (two-tailed, no adjustment for multiple comparisons because of one correlation test for a gene pair). The values of the coefficients (r) and significance (p) are indicated. f ) Kaplan-Meier analysis of OS of patient cohorts expressing differential FceM1 signature (top 33% vs bottom 33%) based on combined log-averaging of CD68 , CD86 and FCER1A transcript levels from the TCGA-SKCM dataset. P value is generated using two-tailed LogRank test. Median, median survival time
Figure Legend Snippet: Sera from Prdm1 fl/fl Foxp3 YFP-Cre tumor-bearing mice increase the anti-tumor activity of macrophages. a-b ) B16-OVA model was established as in Fig. c. IF staining of IgE and CD68 in the tumor and quantitation of IgE + CD68 + and IgE + CD68 − cells ( a ); or IF staining of FcεR1α and CD68 in the tumor ( b ). Each dot represents the counted numbers within a field of view (160 ×). WT: n = 15 views from 6 mice; KO: n = 14 views from 6 mice. c-d ) BMDMs were co-cultured with CTV-labelled B16-OVA cells treated with or without a same volume of sera (2.5 μl, 1.25% of the total culture) collected from WT or Prdm1 fl/fl Foxp3 YFP - Cre (KO) tumor-bearing mice for 2 h ( c ) or overnight ( d ) in quadruplicates. In a group, sera were pre-treated with anti-IgE (α-IgE). c ) BMDMs with phagocytosed B16-OVA cells were indicated as CTV + F4/80 + cells ( upper left , representative F4/80 + plot; lower left , representative histogram of CTV expression gated on F4/80 + cells; right , quantitation). d ) Percent tumor killing is shown after quantifying dead tumor cells (CTV + cells positive for viability-dye). Tumor cells alone treated with sera were included as controls. Triangles, tumor cells and BMDMs with no sera added. ns, no significance, * P < 0.05, ** P < 0.01, *** P < 0.001 and **** P < 0.0001 (a,c,d, unpaired two-tailed Student’s t-test). Bars, mean ± SEM. e ) The correlation of CD86 and FCER1A expression in top 25% CD68 hi SKCM patients from the TCGA dataset ( n = 110) was analyzed by Pearson correlation (two-tailed, no adjustment for multiple comparisons because of one correlation test for a gene pair). The values of the coefficients (r) and significance (p) are indicated. f ) Kaplan-Meier analysis of OS of patient cohorts expressing differential FceM1 signature (top 33% vs bottom 33%) based on combined log-averaging of CD68 , CD86 and FCER1A transcript levels from the TCGA-SKCM dataset. P value is generated using two-tailed LogRank test. Median, median survival time

Techniques Used: Activity Assay, Staining, Quantitation Assay, Cell Culture, Expressing, Two Tailed Test, Generated

TIL eTreg cells from Prdm1 fl/fl Foxp3 YFP-Cre mice display distinct transcriptomic profiles. WT or Prdm1 fl/fl Foxp3 YFP-Cre (KO) mice were implanted with B16-OVA and immunized with NP-OVA (as in Fig. c). Splenic and tumoral eTreg cells (CD45 + CD44 + YFP + CD4 + CD3 + ) were sorted for gene expression profiling (duplicates). a ) DEGs in splenic and TIL WT and Blimp1 KO eTreg cells were analyzed by volcano plots and venn diagram. In the plots, each data point represents a gene. The x-axis and y-axis represent the log2 fold change of each gene and the -log10 of its adjusted p -value, respectively. Red dot: the upregulated genes in WT eTreg cells with an adjusted p-value < 0.05 and a log2 fold change > 1. Blue dots: the downregulated genes in WT eTreg cells with an adjusted p-value < 0.05 and a log2 fold change < − 1. Some genes involved in the regulation of Treg cells are denoted. b ) Principal component analysis of all 4 subsets. SP: spleen; TU: tumor. c ) Pathway enrichment of TIL WT and KO eTreg cells is presented by scatter plot and top biological pathways. pORA: probability of over-representation; pAcc: probability of accumulation. Right , P values are listed in the accompanying table. d ) List of DEGs (at a > 2 log -fold change and P < 0.05) of TIL WT and KO eTreg cells related to Treg stability or NK cell and cytotoxicity
Figure Legend Snippet: TIL eTreg cells from Prdm1 fl/fl Foxp3 YFP-Cre mice display distinct transcriptomic profiles. WT or Prdm1 fl/fl Foxp3 YFP-Cre (KO) mice were implanted with B16-OVA and immunized with NP-OVA (as in Fig. c). Splenic and tumoral eTreg cells (CD45 + CD44 + YFP + CD4 + CD3 + ) were sorted for gene expression profiling (duplicates). a ) DEGs in splenic and TIL WT and Blimp1 KO eTreg cells were analyzed by volcano plots and venn diagram. In the plots, each data point represents a gene. The x-axis and y-axis represent the log2 fold change of each gene and the -log10 of its adjusted p -value, respectively. Red dot: the upregulated genes in WT eTreg cells with an adjusted p-value < 0.05 and a log2 fold change > 1. Blue dots: the downregulated genes in WT eTreg cells with an adjusted p-value < 0.05 and a log2 fold change < − 1. Some genes involved in the regulation of Treg cells are denoted. b ) Principal component analysis of all 4 subsets. SP: spleen; TU: tumor. c ) Pathway enrichment of TIL WT and KO eTreg cells is presented by scatter plot and top biological pathways. pORA: probability of over-representation; pAcc: probability of accumulation. Right , P values are listed in the accompanying table. d ) List of DEGs (at a > 2 log -fold change and P < 0.05) of TIL WT and KO eTreg cells related to Treg stability or NK cell and cytotoxicity

Techniques Used: Expressing

Deletion of Eomes in Blimp1-deficient Treg cells promotes tumor growth. a ) Comparison and quantitation of Eomes levels in TIL Treg cells from B16-OVA/NP-OVA mice (n = 8 per group), as in Fig. c. b ) B16-OVA model was established in each mouse strain (WT: n = 7; KO: n = 6; DKO: n = 5), as in Fig. c. Tumor sizes are shown. c ) Comparison ad quantitation of Eomes MFI in TIL Treg cells from b. The vertical dotted line represents the threshold for the gating of Eomes + cells. d ) Frequency of TIL Treg and T FR cells (PD-1 + Bcl6 + Foxp3 + CD4 + CD3 + ) and Foxp3 MFI of Treg cells as well as TIL Treg cells expressing IFNγ and GzmB or CD8 + T-cells expressing GzmB. e ) Frequency of TIL T FH (PD-1 + Bcl6 + Foxp3 − CD4 + CD3 + ) and GC B-cells (GL-7 + Fas + CD19 + ). f ) Serum total IgG, IgE and anti-OVA IgG, IgE titers. The value 0 is used to indicate the undetectable anti-OVA IgE titers. In c-f, WT: n = 5-6; KO: n = 4-5; DKO: n = 5-8. Iso: Isotype control. WT: Foxp3 YFP-Cre , KO: Prdm1 fl/fl Foxp3 YFP-Cre , DKO: Eomes fl/fl Prdm1 fl/fl Foxp3 YFP-Cre . ∆MFI: MFI subtracted from the MFI of isotype controls. Data are pooled from two (a) or represent one of two independent experiments (b-f). ns, no significance, * P < 0.05, ** P < 0.01, *** P < 0.001 and **** P < 0.001 (a,c,d-f, unpaired two-tailed Student’s t-test; b, two-way ANOVA with Tukey’s comparisons test, black: compared to WT, red: compared to KO). Bars, mean ± SEM
Figure Legend Snippet: Deletion of Eomes in Blimp1-deficient Treg cells promotes tumor growth. a ) Comparison and quantitation of Eomes levels in TIL Treg cells from B16-OVA/NP-OVA mice (n = 8 per group), as in Fig. c. b ) B16-OVA model was established in each mouse strain (WT: n = 7; KO: n = 6; DKO: n = 5), as in Fig. c. Tumor sizes are shown. c ) Comparison ad quantitation of Eomes MFI in TIL Treg cells from b. The vertical dotted line represents the threshold for the gating of Eomes + cells. d ) Frequency of TIL Treg and T FR cells (PD-1 + Bcl6 + Foxp3 + CD4 + CD3 + ) and Foxp3 MFI of Treg cells as well as TIL Treg cells expressing IFNγ and GzmB or CD8 + T-cells expressing GzmB. e ) Frequency of TIL T FH (PD-1 + Bcl6 + Foxp3 − CD4 + CD3 + ) and GC B-cells (GL-7 + Fas + CD19 + ). f ) Serum total IgG, IgE and anti-OVA IgG, IgE titers. The value 0 is used to indicate the undetectable anti-OVA IgE titers. In c-f, WT: n = 5-6; KO: n = 4-5; DKO: n = 5-8. Iso: Isotype control. WT: Foxp3 YFP-Cre , KO: Prdm1 fl/fl Foxp3 YFP-Cre , DKO: Eomes fl/fl Prdm1 fl/fl Foxp3 YFP-Cre . ∆MFI: MFI subtracted from the MFI of isotype controls. Data are pooled from two (a) or represent one of two independent experiments (b-f). ns, no significance, * P < 0.05, ** P < 0.01, *** P < 0.001 and **** P < 0.001 (a,c,d-f, unpaired two-tailed Student’s t-test; b, two-way ANOVA with Tukey’s comparisons test, black: compared to WT, red: compared to KO). Bars, mean ± SEM

Techniques Used: Quantitation Assay, Expressing, Two Tailed Test

Deletion of Blimp1 in Treg cells remodels the TME and sensitizes the tumors to anti-PD-1 treatment. a-d ) B16-OVA model was established as in Fig. c. a-b ) CD45 − cells were sorted and subject to NanoString analysis. a ) DEGs related to angiogenesis and type 1 IFN signature (≥ 1.5 fold change and P < 0.05) in Foxp3 YFP-Cre (WT) (n = 3) and Prdm1 fl/fl Foxp3 YFP-Cre (KO) mice ( n = 2). b ) Reactome pathway analysis of DEGs revealed in a via NetworkAnalyst. c ) IF staining of CD31 in the tumor and quantitation of CD31 + structures. Each dot represents the counted numbers within a field of view (160 ×). WT: n = 11 views from 6 mice; KO: n = 13 views from 6 mice. d ) Expression and quantitation of MFI for MHCII and CD74 and percent Ki-67 of CD45 − cells (WT: n = 3; KO: n = 4). e ) Mice (WT + Ctrl, WT + a-PD-1, KO + a-PD-1: n = 5; KO + Ctrl: n = 4) were inoculated with B16-OVA (as in Fig. c) and treated with a-PD-1 or isotype control (Ctrl) Ab at days 3,6,9 post-implantation. Tumor volumes are shown. Upper , each dot represents an average of tumor volumes at a single day. Bottom , individual mouse at each day. WT: Foxp3 YFP-Cre , KO: Prdm1 fl/fl Foxp3 YFP-Cre . ns, no significance, * P < 0.05, ** P < 0.01 and *** P < 0.001 (c-d, e ( upper ), unpaired two-tailed Student’s t-test; e ( bottom ), two-way ANOVA with Tukey’s comparisons test, Day 20: **, WT + Ctrl vs. WT + a-PD-1; *, WT + Ctrl vs. KO + Ctrl; *, WT + Ctrl vs. KO + a-PD-1. Day 21: **, WT + Ctrl vs. WT + a-PD-1; *, WT + Ctrl vs. KO + Ctrl; **, WT + Ctrl vs. KO + a-PD-1. Day 26: **, WT + Ctrl vs. WT + a-PD-1; **, WT + Ctrl vs. KO + Ctrl; ****, WT + Ctrl vs. KO + a-PD-1. Day 28: *, WT + a-PD-1 vs. KO + Ctrl; ***, WT + a-PD-1 vs. KO + a-PD-1). Bars, mean ± SEM
Figure Legend Snippet: Deletion of Blimp1 in Treg cells remodels the TME and sensitizes the tumors to anti-PD-1 treatment. a-d ) B16-OVA model was established as in Fig. c. a-b ) CD45 − cells were sorted and subject to NanoString analysis. a ) DEGs related to angiogenesis and type 1 IFN signature (≥ 1.5 fold change and P < 0.05) in Foxp3 YFP-Cre (WT) (n = 3) and Prdm1 fl/fl Foxp3 YFP-Cre (KO) mice ( n = 2). b ) Reactome pathway analysis of DEGs revealed in a via NetworkAnalyst. c ) IF staining of CD31 in the tumor and quantitation of CD31 + structures. Each dot represents the counted numbers within a field of view (160 ×). WT: n = 11 views from 6 mice; KO: n = 13 views from 6 mice. d ) Expression and quantitation of MFI for MHCII and CD74 and percent Ki-67 of CD45 − cells (WT: n = 3; KO: n = 4). e ) Mice (WT + Ctrl, WT + a-PD-1, KO + a-PD-1: n = 5; KO + Ctrl: n = 4) were inoculated with B16-OVA (as in Fig. c) and treated with a-PD-1 or isotype control (Ctrl) Ab at days 3,6,9 post-implantation. Tumor volumes are shown. Upper , each dot represents an average of tumor volumes at a single day. Bottom , individual mouse at each day. WT: Foxp3 YFP-Cre , KO: Prdm1 fl/fl Foxp3 YFP-Cre . ns, no significance, * P < 0.05, ** P < 0.01 and *** P < 0.001 (c-d, e ( upper ), unpaired two-tailed Student’s t-test; e ( bottom ), two-way ANOVA with Tukey’s comparisons test, Day 20: **, WT + Ctrl vs. WT + a-PD-1; *, WT + Ctrl vs. KO + Ctrl; *, WT + Ctrl vs. KO + a-PD-1. Day 21: **, WT + Ctrl vs. WT + a-PD-1; *, WT + Ctrl vs. KO + Ctrl; **, WT + Ctrl vs. KO + a-PD-1. Day 26: **, WT + Ctrl vs. WT + a-PD-1; **, WT + Ctrl vs. KO + Ctrl; ****, WT + Ctrl vs. KO + a-PD-1. Day 28: *, WT + a-PD-1 vs. KO + Ctrl; ***, WT + a-PD-1 vs. KO + a-PD-1). Bars, mean ± SEM

Techniques Used: Staining, Quantitation Assay, Expressing, Two Tailed Test


Structured Review

Millipore hen egg white ovalbumin grade v ova
Hen Egg White Ovalbumin Grade V Ova, supplied by Millipore, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/hen egg white ovalbumin grade v ova/product/Millipore
Average 86 stars, based on 1 article reviews
Price from $9.99 to $1999.99
hen egg white ovalbumin grade v ova - by Bioz Stars, 2024-04
86/100 stars

Images


Structured Review

Millipore ovalbumin ova
Ovalbumin Ova, supplied by Millipore, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ovalbumin ova/product/Millipore
Average 86 stars, based on 1 article reviews
Price from $9.99 to $1999.99
ovalbumin ova - by Bioz Stars, 2024-04
86/100 stars

Images


Structured Review

Millipore hen egg white ovalbumin grade v ova

Hen Egg White Ovalbumin Grade V Ova, supplied by Millipore, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/hen egg white ovalbumin grade v ova/product/Millipore
Average 86 stars, based on 1 article reviews
Price from $9.99 to $1999.99
hen egg white ovalbumin grade v ova - by Bioz Stars, 2024-04
86/100 stars

Images

1) Product Images from "Programming Multifaceted Pulmonary T Cell Immunity by Combination Adjuvants"

Article Title: Programming Multifaceted Pulmonary T Cell Immunity by Combination Adjuvants

Journal: Cell Reports Medicine

doi: 10.1016/j.xcrm.2020.100095


Figure Legend Snippet:

Techniques Used: Blocking Assay, Derivative Assay, Recombinant, Protein Extraction, Staining, Electron Microscopy, Cell Culture, Enzyme-linked Immunosorbent Assay, Software


Structured Review

Millipore ovalbumin ova
Phosphorylation levels <t>of</t> <t>SHP2</t> and ROCK in eosinophils from BALFs of children with allergic asthma or FBA and of mice sensitized with <t>OVA</t> and challenged with OVA or NS. A, B) BALF cells from children with FBA or asthma were used for immunostaining of CCR3 and p-Y542-SHP2 and p-S1366-ROCK2 or isotype IgG of p-SHP2 (Y542), p-S1366-ROCK2, and DAPI, and subsequent quantification of p-Y542-SHP2 or p-S1366-ROCK2 in CCR3-positive cells. C, D) OVA-sensitized mice were aerosolized with 1% OVA or an equal volume of NS for 30 min once daily for 7 d. Twenty-four hours after the last OVA challenge, BALF cells were prepared for the immunostaining of CCR3, p-Y542-SHP2, p-S1366-ROCK2, and DAPI, and subsequent quantification of p-Y542-SHP2 or p-S1366-ROCK2 in CCR3-positive cells. White arrows indicate the positive p-Y542-SHP2 or p-S1366-ROCK2 staining in CCR3-stained cells. Children with FBA (n = 4); children with asthma (n = 7); mouse model, (n = 3). Representative results are shown. **P < 0.01 vs. children with FBA or mice challenged with NS.
Ovalbumin Ova, supplied by Millipore, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ovalbumin ova/product/Millipore
Average 86 stars, based on 1 article reviews
Price from $9.99 to $1999.99
ovalbumin ova - by Bioz Stars, 2024-04
86/100 stars

Images

1) Product Images from "Protein tyrosine phosphatase 11 acts through RhoA/ROCK to regulate eosinophil accumulation in the allergic airway"

Article Title: Protein tyrosine phosphatase 11 acts through RhoA/ROCK to regulate eosinophil accumulation in the allergic airway

Journal: The FASEB Journal

doi: 10.1096/fj.201900698R

Phosphorylation levels of SHP2 and ROCK in eosinophils from BALFs of children with allergic asthma or FBA and of mice sensitized with OVA and challenged with OVA or NS. A, B) BALF cells from children with FBA or asthma were used for immunostaining of CCR3 and p-Y542-SHP2 and p-S1366-ROCK2 or isotype IgG of p-SHP2 (Y542), p-S1366-ROCK2, and DAPI, and subsequent quantification of p-Y542-SHP2 or p-S1366-ROCK2 in CCR3-positive cells. C, D) OVA-sensitized mice were aerosolized with 1% OVA or an equal volume of NS for 30 min once daily for 7 d. Twenty-four hours after the last OVA challenge, BALF cells were prepared for the immunostaining of CCR3, p-Y542-SHP2, p-S1366-ROCK2, and DAPI, and subsequent quantification of p-Y542-SHP2 or p-S1366-ROCK2 in CCR3-positive cells. White arrows indicate the positive p-Y542-SHP2 or p-S1366-ROCK2 staining in CCR3-stained cells. Children with FBA (n = 4); children with asthma (n = 7); mouse model, (n = 3). Representative results are shown. **P < 0.01 vs. children with FBA or mice challenged with NS.
Figure Legend Snippet: Phosphorylation levels of SHP2 and ROCK in eosinophils from BALFs of children with allergic asthma or FBA and of mice sensitized with OVA and challenged with OVA or NS. A, B) BALF cells from children with FBA or asthma were used for immunostaining of CCR3 and p-Y542-SHP2 and p-S1366-ROCK2 or isotype IgG of p-SHP2 (Y542), p-S1366-ROCK2, and DAPI, and subsequent quantification of p-Y542-SHP2 or p-S1366-ROCK2 in CCR3-positive cells. C, D) OVA-sensitized mice were aerosolized with 1% OVA or an equal volume of NS for 30 min once daily for 7 d. Twenty-four hours after the last OVA challenge, BALF cells were prepared for the immunostaining of CCR3, p-Y542-SHP2, p-S1366-ROCK2, and DAPI, and subsequent quantification of p-Y542-SHP2 or p-S1366-ROCK2 in CCR3-positive cells. White arrows indicate the positive p-Y542-SHP2 or p-S1366-ROCK2 staining in CCR3-stained cells. Children with FBA (n = 4); children with asthma (n = 7); mouse model, (n = 3). Representative results are shown. **P < 0.01 vs. children with FBA or mice challenged with NS.

Techniques Used: Immunostaining, Staining

Effects of SHP2 deletion in myeloid cells on the inflammatory cell infiltration into lungs and airway hyperreactivity. Mice with the indicated genotypes were sensitized and subsequently challenged with OVA; 24 h after the final OVA challenge, mice were subjected to preparation of BALFs for inflammatory cell counting and classification (A), paraffin-embedded sections, H&E staining, and CCR3 immunostaining (B), and examination of methacholine-provoked airway hyperrreactivity (C) (n = 6). +P < 0.05; ++P < 0.01 vs. SHP2f/f mice challenged with NS; *P < 0.05; **P < 0.01 vs. SHP2f/f mice challenged with OVA. Square frames define the magnified regions.
Figure Legend Snippet: Effects of SHP2 deletion in myeloid cells on the inflammatory cell infiltration into lungs and airway hyperreactivity. Mice with the indicated genotypes were sensitized and subsequently challenged with OVA; 24 h after the final OVA challenge, mice were subjected to preparation of BALFs for inflammatory cell counting and classification (A), paraffin-embedded sections, H&E staining, and CCR3 immunostaining (B), and examination of methacholine-provoked airway hyperrreactivity (C) (n = 6). +P < 0.05; ++P < 0.01 vs. SHP2f/f mice challenged with NS; *P < 0.05; **P < 0.01 vs. SHP2f/f mice challenged with OVA. Square frames define the magnified regions.

Techniques Used: Cell Counting, Staining, Immunostaining

Effects of overexpression of dnRhoA on SHP2 deletion–resultant inflammatory cell infiltration into lungs and airway hyperreactivity. Mice with the indicated genotypes were sensitized and subsequently challenged with OVA; 24 h after the last OVA challenge, mice were subjected to preparation of BALFs for inflammatory cell counting and classification (A), paraffin-embedded sections, H&E staining, and CCR3 immunostaining (B), examination of methacholine-provoked airway hyperreactivity (C) (n = 6). Square frames define the magnified regions. +P < 0.05; ++P < 0.01 vs. dnRhoA+/−;SHP2f/+ mice challenged with NS; **P < 0.01 vs. dnRhoA+/−;SHP2f/+ mice challenged with OVA; ‡P < 0.01 vs. LysM-Cre;dnRhoA+/− or LysM-Cre;SHP2f/+ mice challenged with OVA.
Figure Legend Snippet: Effects of overexpression of dnRhoA on SHP2 deletion–resultant inflammatory cell infiltration into lungs and airway hyperreactivity. Mice with the indicated genotypes were sensitized and subsequently challenged with OVA; 24 h after the last OVA challenge, mice were subjected to preparation of BALFs for inflammatory cell counting and classification (A), paraffin-embedded sections, H&E staining, and CCR3 immunostaining (B), examination of methacholine-provoked airway hyperreactivity (C) (n = 6). Square frames define the magnified regions. +P < 0.05; ++P < 0.01 vs. dnRhoA+/−;SHP2f/+ mice challenged with NS; **P < 0.01 vs. dnRhoA+/−;SHP2f/+ mice challenged with OVA; ‡P < 0.01 vs. LysM-Cre;dnRhoA+/− or LysM-Cre;SHP2f/+ mice challenged with OVA.

Techniques Used: Over Expression, Cell Counting, Staining, Immunostaining

Effects of overexpression of caRhoA on SHP2 deletion–resultant inflammatory cell infiltration into lungs and airway hyperreactivity. Mice with the indicated genotypes were sensitized and subsequently challenged with OVA; 24 h after the last OVA challenge, mice were subjected to preparation of BALFs for inflammatory cell counting and classification (A), paraffin-embedded sections, H&E staining, and CCR3 immunostaining (B), examination of methacholine-provoked airway hyperreactivity (C) (n = 6). Square frames define the magnifiesd regions. +P < 0.05; ++P < 0.01 vs. caRhoA+/−;SHP2f/f mice challenged with NS; *P < 0.05; **P < 0.01 vs. caRhoA+/−;SHP2f/f mice challenged with OVA; †P < 0.05; ‡P < 0.01 vs. LysM-Cre;SHP2f/f mice challenged with OVA.
Figure Legend Snippet: Effects of overexpression of caRhoA on SHP2 deletion–resultant inflammatory cell infiltration into lungs and airway hyperreactivity. Mice with the indicated genotypes were sensitized and subsequently challenged with OVA; 24 h after the last OVA challenge, mice were subjected to preparation of BALFs for inflammatory cell counting and classification (A), paraffin-embedded sections, H&E staining, and CCR3 immunostaining (B), examination of methacholine-provoked airway hyperreactivity (C) (n = 6). Square frames define the magnifiesd regions. +P < 0.05; ++P < 0.01 vs. caRhoA+/−;SHP2f/f mice challenged with NS; *P < 0.05; **P < 0.01 vs. caRhoA+/−;SHP2f/f mice challenged with OVA; †P < 0.05; ‡P < 0.01 vs. LysM-Cre;SHP2f/f mice challenged with OVA.

Techniques Used: Over Expression, Cell Counting, Staining, Immunostaining

Similar Products

No Results Found